DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Confavreux C, O'Connor P, Comi G. , et al; TOWER Trial Group.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Neurol 2014;
13 (03) 247-256
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.